高非球面微透镜框架眼镜用于美国儿童近视控制:随机临床试验
这项双盲随机临床试验在美国9个中心纳入6至12岁、等效球镜度-0.75至-4.50D的近视儿童,比较高非球面微透镜(HAL)框架眼镜与单光框架眼镜(SVL)的24个月安全性和有效性。结果显示HAL组近视进展和眼轴增长均显著低于SVL组,最佳矫正视力两组相当,未见严重或与镜片相关的不良事件。
要点
- HAL组24个月近视进展比SVL组少0.64D,相对减少71%。
- HAL组24个月眼轴增长比SVL组少0.24mm,相对减少53%。
- 两组最佳矫正视力相当,无严重或与镜片相关的不良事件。
核心结论
- 在美国儿童中,HAL框架眼镜在24个月内减少了近视进展和眼轴增长。
- HAL框架眼镜在本研究中表现出安全性和有效性,支持其作为近视控制干预措施。
研究设计与样本
- 双盲随机临床试验,在美国9个研究点开展。
- 纳入6至12岁、显性等效球镜度为-0.75至-4.50D的儿童,按1:1随机分配至HAL组或SVL组。
- 共随机159名参与者,135名(84.9%)完成24个月评估。
主要发现
- 24个月时,HAL组调整后平均近视进展为-0.25D,SVL组为-0.90D,差异0.64D(95%CI 0.50至0.79,P<.001),相对减少71%。
- 24个月时,HAL组调整后平均眼轴增长为0.21mm,SVL组为0.45mm,差异-0.24mm(95%CI -0.29至-0.19,P<.001),相对减少53%。
- 最佳矫正视力两组相当,平均差异-0.01 logMAR(95%CI -0.02至0.00,P=.23)。
- 眼部不良事件HAL组77名中9名(11.7%),SVL组82名中12名(14.6%),无严重或与镜片相关的事件。
- 主观症状报告总数HAL组19次,SVL组25次。
关键数值与推荐
- 纳入标准为显性等效球镜度-0.75至-4.50D。
- 主要结局为24个月环戊通等效球镜度(cSER)和眼轴长度变化。
临床怎么用
- 对于符合条件的美国近视儿童,HAL框架眼镜可作为近视控制的安全有效选择。
- 研究结果支持HAL作为近视控制干预措施,并构成FDA对该研究器械授权的基础。
局限性
- 需要更长期数据评估持续治疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Myopia prevalence is rising in the US. Spectacle lenses with highly aspherical lenslets (HAL) are effective in Asian populations but unproven in US children. OBJECTIVE: To evaluate the 24-month safety and effectiveness of HAL spectacle lenses compared with single-vision spectacle lenses (SVL) in US children with myopia. DESIGN, SETTING, AND PARTICIPANTS: This double-masked randomized clinical trial took place at 9 investigational sites in the US and included children aged 6 to 12 years with a manifest spherical equivalent refraction (SER) of -0.75 to -4.50 diopters (D). Key exclusion criteria included a history of prior myopia control intervention, strabismus, amblyopia, or any ocular or systemic conditions and medications affecting refractive status. Enrollment was from December 2021 to July 2022, and the 24-month follow-up reported here was completed in October 2024. INTERVENTIONS: Participants were randomized (1:1) to HAL or SVL. MAIN OUTCOMES AND MEASURES: Primary outcomes were 24-month changes in cycloplegic SER (cSER) and axial length. RESULTS: Of 159 randomized participants (80 [50.3%] male; mean [SD] age, 9.7 [1.6] years), 135 (84.9%) completed the 24-month assessment. The baseline mean (SD) cSER was -2.21 (1.07) D in the HAL group and -2.05 (1.22) D in the SVL group. At 24 months, adjusted mean (SE) myopia progression was -0.25 (0.05) D in the HAL group and -0.90 (0.05) D in the SVL group (difference, 0.64 D; 95% CI, 0.50 to 0.79; P < .001), a 71% relative reduction. The baseline mean (SD) axial length was 24.26 (0.92) mm in the HAL group and 24.32 (0.83) mm in the SVL group. Adjusted mean (SE) axial elongation was 0.21 (0.02) mm in the HAL group and 0.45 (0.02) mm in the SVL group (difference, -0.24 mm; 95% CI, -0.29 to -0.19; P < .001), a 53% relative reduction. Best-corrected visual acuity was equivalent between groups (mean difference, -0.01 logMAR; 95% CI, -0.02 to 0.00; P = .23). Ocular adverse events occurred in 9 of 77 participants the HAL group (11.7%) vs 12 of 82 in the SVL group (14.6%); none were serious or lens related. The total number of subjective symptom reports were 19 (HAL) and 25 (SVL). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of US children, spectacle lenses with HAL provided a reduction in myopia progression and axial elongation over 24 months. While longer-term data are needed to evaluate sustained treatment efficacy, these findings support HAL as a safe and effective myopia control intervention and underlie US Food and Drug Administration authorization of the study device. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05174780.
引用
- Shen J, Hunt C, Young G, et al. Spectacle Lenses With Highly Aspherical Lenslets for Myopia Control: A Randomized Clinical Trial. JAMA Ophthalmol. 2026. PMID: 42623028. doi:10.1001/jamaophthalmol.2026.3288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。